Can a smartphone app help latina breast cancer patients beat the odds?

NCT ID NCT07706127

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether a bilingual smartphone app, combined with patient navigation, can help Latina breast cancer patients take their hormone therapy as prescribed. Many patients struggle with barriers like cost, insurance, or language that make it hard to stay on treatment. The goal is to improve medication adherence, reduce cancer recurrence, and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HT Helper app plus patient navigation support
What this could lead to
If effective, this approach could help Latina breast cancer patients take their hormone therapy more consistently, potentially reducing cancer recurrence and improving survival.
What could go wrong
This is a relatively small, single-center trial, and the app's benefits may not extend to other populations or settings. Adherence improvements may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE-RECEPTOR-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas Health Science Center at San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.